Ann: COVID ARDS Trial Topline 60-Day Results, page-604

In general 65+ age group is and has always had a major challenge in responding to any standard of care treatment for hundreds if not thousands of ailments so this is not new news and should not be seen as a downside or bad outcome for MSB’s Reml treatment - 65+ is just the highest risk group of death due to various compounded reasons when they are exposed to a major trauma or disease/virus.

For example it is known in the hospital I work in that if a patient is 80+ years of age and breaks a hip they know that 90% of patients will not survive the trauma in the near to medium term no matter what standard of care is provided. 65+ would be around sit above 50% death rate.

Yes a hip break is a major trauma and most of us know that is very very bad for an elderly person but as we have learnt COVID 19 is a major trauma on the body as well as we see the massive compounded effects of the virus on the body(trauma)- worst for the 65+ Unfortunately.

Patients under 65 can sustain trauma and immobility as their body functions, strength as well as mental functions are just much better so they can naturally withstand the compounded effects of the trauma.

Refer here to the link here for some of what I have talked about but their are many articles written about the elderly 65+ and major trauma of some sort is massively compounded and unfortunately a high death rate percentage is the common outcome.
https://theconversation.com/why-hip-fractures-in-the-elderly-are-often-a-death-sentence-95784

It is apparent that thousands of SOC treatments including Reml will just not assist 65+ patients very much due to compounding physical and mental factors. Does not mean we can’t still try but it shows easily why Reml will assist the 65 and under age group more and this ideally should have been the endpoint focus from a commercial sense however the NIH were simply focused on worst affected and rightly so but it was also going to be a very big ask in the 65+ bracket. I see the outcome of the NIH trial as an already known really in hindsight.

Now we know like many other SOC for traumas and diseases - MSB treatments achieve better outcomes where the bodies are healthy enough to respond to it and be able to handle the recovery period.

Looking forward to the next exciting chapters for MSB since now MSB and all of us know precisely what, when and who the treatments best work on. This can be proven further and shown to the world.